

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: YOUNGRO BYUN et al.)
)
TITLE: DRUG RELEASE FROM)
ANTITHROMBOGENIC)
MULTI-LAYER COATED)
STENT)
)
SERIAL NO.: 10/797,629) INFORMATION DISCLOSURE
) STATEMENT UNDER 37 C.F.R.
FILED: March 9, 2004) § 1.97
)
EXAMINER _____)
)
ART UNIT: _____)
)
)


Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form PTO-1449, which contains a list of patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). Applicant respectfully invokes the Patent Office's obligation under 37 C.F.R. § 1.97 to consider these references and make them of record in the

Certificate of Deposit Under 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the 27th day of July, 2004.


Alan J. Howarth, Ph.D.
Attorney Registration No. 36,553

above-captioned application. While no representation is made that any of these references may be "prior art" within the meaning of that term under 35 U.S.C. §§ 102 or 103, the enclosed list of references is disclosed so as to fully comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.

Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney of record believes that the references listed, together with any other references which may have been previously cited by or submitted to the Office, are the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.

In accordance with 37 C.F.R. §§ 1.97 and 1.98, a copy of each listed reference (or relevant portion thereof) that was not previously submitted to, or cited by, the Patent Office is also enclosed.

Statement of References Previously Disclosed
Under 37 C.F.R. § 1.98(d)

The references listed on the enclosed Form PTO-1449 are not required to be provided under 37 C.F.R. § 1.98(d), and are therefore not enclosed, because they were previously cited by or submitted to the Office in application number 10/262,432, which is relied upon for an earlier filing date under 35 U.S.C. § 120.

Please charge any additional fees or credit any overpayment to
Deposit Account No. 50-0836.

DATED this 27th day of July, 2004.

Respectfully submitted,




Alan J. Howarth, Ph.D.
Attorney Registration No. 36,553

CLAYTON, HOWARTH & CANNON, P.C.
P.O. Box 1909
Sandy, UT 84091
Telephone: (801) 255-5335
Facsimile: (801) 255-5338

AJH/tet

S:\CHC Files\T 9--\T99--\T9983\A\IDS.wpd



PTO-144

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. T9983.A

SERIAL NO. 10/797,629

LIST OF PRIOR ART CITED BY APPLICANT

APPLICANT Youngro Byun et al.

FILING DATE March 9, 2004

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,239,754	Dec. 16, 1980	Sache et al.			
	AB	4,857,602	Aug. 15, 1989	Casey et al.			
	AC	5,536,508	Jul. 16, 1996	Canal et al.			
	AD	5,626,869	May 6, 1997	Nyqvist et al.			
	AE	5,700,486	Dec. 23, 1997	Canal et al.			
	AF	5,744,155	Apr. 28, 1998	Friedman et al.			
	AG	5,782,908	Jul. 1998	Cahalan et al.			
	AH	5,820,881	Oct. 13, 1998	Milstein			
	AI	5,837,313	Nov. 17, 1998	Ding et al.			
	AJ	5,840,387	Nov. 24, 1998	Berlowitz-Tarrant et al.			
	AK	5,855,618	Jan. 5, 1999	Patnaik et al.			
	AL	5,993,846	Nov. 30, 1999	Friedman et al.			
	AM	5,993,972	Nov. 1999	Reich et al.			
	AN	6,153,252	Nov. 2000	Hossainy et al.			
	AO	6,190,591	Feb. 20, 2001	van Lengerich			
	AP	6,245,753	Jun. 12, 2001	Byun et al.			
	AQ	6,248,363	Jun. 19, 2001	Patel et al.			
	AR	6,251,428	Jun. 26, 2001	Yoo			
	AS	6,258,121	Jul. 10, 2001	Yang et al.			
	AT	6,306,144	Oct. 23, 2001	Sydney et al.			
	AU	6,355,058	Mar. 12, 2002	Pacetti et al.			
	AV	6,361,819	Mar. 2002	Tedeschi et al.			
	AW	6,376,242	Apr. 2002	Hanson			
	AX	6,395,253	May 2002	Levy et al.			
	AY	6,399,144	Jun. 2002	Dinh et al.			
	AZ	US 2002/0091433	Jul. 11, 2002	Ding et al.			

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. T9983.A		SERIAL NO. 10/797,629	
LIST OF PRIOR ART CITED BY APPLICANT				APPLICANT Youngro Byun et al.			
				FILING DATE March 9, 2004		GROUP	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BA	WO 00/13719	16 Mar 00	PCT			X
	BB	WO 02/34312	2 May 02	PCT			X
OTHER PRIOR ART (Including Author, Title, Volume and/or Name of Publication, Relevant Pages and Date [as available])							
	BC		R. Altman et al. Oral Anticoagulant Treatment with and without Aspirin, <i>Thrombosis and Haemostasis</i> , 74, 506-510 (1995).				
	BD		D. Brayden et al. Heparin Absorption Across the Intestine: Effects of Sodium N-[8-(2-Hydroxybenzoyl)Amino]Caprylate in Rate <i>In Situ</i> Intestinal Instillations and in Caco-2 Monolayers, <i>Pharmaceutical Research</i> , 14, 1772-1779 (1997).				
	BE		F. Diancourt et al. Chemical Modifications of Heparin. II. Hydrophobization of Partially N-Desulfated Heparin, <i>Journal of Bioactive and Compatible Polymers</i> , 11, 203-218 (1996).				
	BF		R.D. Hull, MD et al. Hirudin versus heparin and low-molecular-weight heparin: And the winner is... <i>J Lab Clin Med</i> , 132, 171-174, (1998).				
	BG		P. Klement et al. Hirudin causes more bleeding than heparin in a rabbit ear bleeding model, <i>J Lab Clin Med</i> 132, 181-185 (1998).				
	BH		B.G. Koefoed et al. Effect of Fixed Minidose Warfarin, Conventional Dose Warfarin and Aspirin on INR and Prothrombin Fragment 1 + 2 in Patients with Atrial Fibrillation, <i>Thrombosis and Haemostasis</i> , 77, 845-848 (1997).				
	BI		Y-k Lee, et al. Preparation of Slightly Hydrophobic Heparin Derivatives which Can Be Used for Solvent Casting in Polymeric Formulation, <i>Thrombosis Research</i> 92, 149-156 (1998).				
	BJ		Y-k Lee et al. Oral Delivery of New Heparin Derivatives in Rats, <i>Pharmaceutical Research</i> , 17, 1-5 (2000).				
	BK		A. Leone-Bay et al. 4-[4[(2-Hydroxybenzoyl)amino]phenyl]butyric Acid as a Novel Oral Delivery Agent for Recombinant Human Growth Hormone, <i>J. Med. Chem.</i> , 39, 2571-2578 (1996).				
	BL		A. Leone-Bay et al. The evolution of an oral heparin dosing solution, <i>Drugs of the Future</i> , 22, 885-891 (1997).				
	BM		A. Leone-Bay et al. Oral Delivery of Sodium Cromolyn: Preliminary Studies <i>In Vivo</i> and <i>In Vitro</i> , <i>Pharmaceutical Research</i> , 13, 222-226 (1996).				
	BN		A. Leone-Bay et al. N-Acylated α -Amino Acids as Novel Oral Delivery Agents for Proteins, <i>J. Med. Chem.</i> , 38, 4263-4269 (1995).				
	BO		A. Leone-Bay et al. Acylated non- α -amino acids as novel agents for the oral delivery of heparin sodium, USP, <i>Journal of Controlled Release</i> , 50, 41-49 (1998).				
	BP		A. Leone-Bay et al. Synthesis and Evaluation of Compounds That Facilitate the Gastrointestinal Absorption of Heparin, <i>J. Med. Chem.</i> , 41, 1163-1171 (1998).				
	BQ		A. Leone-Bay et al. Microsphere Formation in a Series of Derivatized α -Amino Acids: Properties, Molecular Modeling, and Oral Delivery of Salmon Calcitonin, <i>J. Med. Chem.</i> , 38, 4257-4262 (1995).				

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

--

OTHER PRIOR ART (Including Author, Title, Volume and/or Name of Publication, Relevant Pages and Date (as available))

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPER 600. Draw line through citation if not in conformance.

2. **REMARKS:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.